250 related articles for article (PubMed ID: 21471143)
1. Differential expression of microRNA-675, microRNA-139-3p and microRNA-335 in benign and malignant adrenocortical tumours.
Schmitz KJ; Helwig J; Bertram S; Sheu SY; Suttorp AC; Seggewiss J; Willscher E; Walz MK; Worm K; Schmid KW
J Clin Pathol; 2011 Jun; 64(6):529-35. PubMed ID: 21471143
[TBL] [Abstract][Full Text] [Related]
2. Distinguishing adrenal cortical carcinomas and adenomas: a study of clinicopathological features and biomarkers.
Wang C; Sun Y; Wu H; Zhao D; Chen J
Histopathology; 2014 Mar; 64(4):567-76. PubMed ID: 24102952
[TBL] [Abstract][Full Text] [Related]
3. Microarray gene expression and immunohistochemistry analyses of adrenocortical tumors identify IGF2 and Ki-67 as useful in differentiating carcinomas from adenomas.
Soon PS; Gill AJ; Benn DE; Clarkson A; Robinson BG; McDonald KL; Sidhu SB
Endocr Relat Cancer; 2009 Jun; 16(2):573-83. PubMed ID: 19218281
[TBL] [Abstract][Full Text] [Related]
4. Analysis of circulating extracellular vesicle-associated microRNAs in cortisol-producing adrenocortical tumors.
Perge P; Decmann Á; Pezzani R; Bancos I; Fassina A; Luconi M; Canu L; Tóth M; Boscaro M; Patócs A; Igaz P
Endocrine; 2018 Feb; 59(2):280-287. PubMed ID: 29299796
[TBL] [Abstract][Full Text] [Related]
5. Analysis of circulating microRNAs in adrenocortical tumors.
Szabó DR; Luconi M; Szabó PM; Tóth M; Szücs N; Horányi J; Nagy Z; Mannelli M; Patócs A; Rácz K; Igaz P
Lab Invest; 2014 Mar; 94(3):331-9. PubMed ID: 24336071
[TBL] [Abstract][Full Text] [Related]
6. Lower expression of ATM and gene deletion is more frequent in adrenocortical carcinomas than adrenocortical adenomas.
Ye J; Qi Y; Wang W; Sun F; Wei Q; Su T; Zhou W; Jiang Y; Yuan W; Cai J; Cui B; Ning G
Endocrine; 2012 Jun; 41(3):479-86. PubMed ID: 22311173
[TBL] [Abstract][Full Text] [Related]
7. Characterization of the mTOR pathway in human normal adrenal and adrenocortical tumors.
De Martino MC; Feelders RA; de Herder WW; van Koetsveld PM; Dogan F; Janssen JA; Waaijers AM; Pivonello C; Lamberts SW; Colao A; de Krijger RR; Pivonello R; Hofland LJ
Endocr Relat Cancer; 2014 Aug; 21(4):601-13. PubMed ID: 24891456
[TBL] [Abstract][Full Text] [Related]
8. Long Noncoding RNA Expression in Adrenal Cortical Neoplasms.
Shiyanbola O; Hardin H; Hu R; Eickhoff JC; Lloyd RV
Endocr Pathol; 2020 Dec; 31(4):385-391. PubMed ID: 32725507
[TBL] [Abstract][Full Text] [Related]
9. DNA and kinetic heterogeneity during the clonal evolution of adrenocortical proliferative lesions.
Blanes A; Diaz-Cano SJ
Hum Pathol; 2006 Oct; 37(10):1295-303. PubMed ID: 16949934
[TBL] [Abstract][Full Text] [Related]
10. The role of microRNA deregulation in the pathogenesis of adrenocortical carcinoma.
Özata DM; Caramuta S; Velázquez-Fernández D; Akçakaya P; Xie H; Höög A; Zedenius J; Bäckdahl M; Larsson C; Lui WO
Endocr Relat Cancer; 2011 Oct; 18(6):643-55. PubMed ID: 21859927
[TBL] [Abstract][Full Text] [Related]
11. Dysregulation of microRNAs in adrenocortical tumors.
Singh P; Soon PS; Feige JJ; Chabre O; Zhao JT; Cherradi N; Lalli E; Sidhu SB
Mol Cell Endocrinol; 2012 Mar; 351(1):118-28. PubMed ID: 21996374
[TBL] [Abstract][Full Text] [Related]
12. Methylation of IGF2 regulatory regions to diagnose adrenocortical carcinomas.
Creemers SG; van Koetsveld PM; van Kemenade FJ; Papathomas TG; Franssen GJ; Dogan F; Eekhoff EM; van der Valk P; de Herder WW; Janssen JA; Feelders RA; Hofland LJ
Endocr Relat Cancer; 2016 Sep; 23(9):727-37. PubMed ID: 27535174
[TBL] [Abstract][Full Text] [Related]
13. [Pathogenic and diagnostic roles of microRNAs in adrenocortical tumours].
Nagy Z; Decmann Á; Perge P; Igaz P
Orv Hetil; 2018 Feb; 159(7):245-251. PubMed ID: 29429354
[TBL] [Abstract][Full Text] [Related]
14. MiR-34a and miR-483-5p are candidate serum biomarkers for adrenocortical tumors.
Patel D; Boufraqech M; Jain M; Zhang L; He M; Gesuwan K; Gulati N; Nilubol N; Fojo T; Kebebew E
Surgery; 2013 Dec; 154(6):1224-8; discussion 1229. PubMed ID: 24238045
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA expression patterns associated with hyperfunctioning and non-hyperfunctioning phenotypes in adrenocortical adenomas.
Velázquez-Fernández D; Caramuta S; Özata DM; Lu M; Höög A; Bäckdahl M; Larsson C; Lui WO; Zedenius J
Eur J Endocrinol; 2014 Apr; 170(4):583-91. PubMed ID: 24446485
[TBL] [Abstract][Full Text] [Related]
16. Next-generation sequencing reveals microRNA markers of adrenocortical tumors malignancy.
Koperski Ł; Kotlarek M; Świerniak M; Kolanowska M; Kubiak A; Górnicka B; Jażdżewski K; Wójcicka A
Oncotarget; 2017 Jul; 8(30):49191-49200. PubMed ID: 28423361
[TBL] [Abstract][Full Text] [Related]
17. Association of Nrf2 expression and mutation with Weiss and Helsinki scores in adrenocortical carcinoma.
Kamai T; Murakami S; Arai K; Ishida K; Kijima T
Cancer Sci; 2022 Jul; 113(7):2368-2377. PubMed ID: 35467062
[TBL] [Abstract][Full Text] [Related]
18. Integrative molecular bioinformatics study of human adrenocortical tumors: microRNA, tissue-specific target prediction, and pathway analysis.
Tömböl Z; Szabó PM; Molnár V; Wiener Z; Tölgyesi G; Horányi J; Riesz P; Reismann P; Patócs A; Likó I; Gaillard RC; Falus A; Rácz K; Igaz P
Endocr Relat Cancer; 2009 Sep; 16(3):895-906. PubMed ID: 19546168
[TBL] [Abstract][Full Text] [Related]
19. Molecular markers and the pathogenesis of adrenocortical cancer.
Soon PS; McDonald KL; Robinson BG; Sidhu SB
Oncologist; 2008 May; 13(5):548-61. PubMed ID: 18515740
[TBL] [Abstract][Full Text] [Related]
20. Specific MicroRNAs Differentiate Adrenocortical Adenomas from Carcinomas and Correlate With Weiss Histopathologic System.
Feinmesser M; Benbassat C; Meiri E; Benjamin H; Lebanony D; Lebenthal Y; de Vries L; Drozd T; Spector Y
Appl Immunohistochem Mol Morphol; 2015 Aug; 23(7):522-31. PubMed ID: 25265426
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
